Today's most important upgrades
By Davit Kirakosyan Etsy (NASDAQ:ETSY) shares rose more than 4% intra-day today after Needham & Company upgraded the company to Buy from Hold with a price target of $160.00, noting that...
Strong Buy
or
Merck&Co News & Analysis
-
-
Bank of America cuts Pfizer on post-COVID uncertainties, upgrades Merck
By Senad Karaahmetovic Bank of America analysts downgraded Pfizer (NYSE:PFE) stock to Neutral from Buy, citing long-term uncertainty. The analysts flag two key concerns: 1) the magnitude...
-
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
PDS Biotechnology Corporation (NASDAQ: PDSB) announced an exclusive global license agreement with Merck KGaA (OTC: MKGAF) (OTC: MKKGY) for the tumor-targeting IL-12 fusion protein M9241...
-
Dow, Nasdaq, and S&P 500 2022 winners and losers: energy, tech lead the way
By Daniel Shvartsman Investing.com -- Entering the last trading day of the year, it's no surprise to find the 2022 scoreboard filled with energy winners and tech losers.The Dow Jones...
-
Overwhelmed by a massive outbreak, China authorizes emergency use of Merck's COVID pill
Beijing's decision to authorize the drug, its second developed abroad after Pfizer's Paxlovid, comes amid domestic shortages of everything from fever-reducing medicines to antivirals that...
-
: China COVID cases could double next month, as Merck antiviral gets approval
China's health service approved an antiviral to treat COVID-19 as one health company estimates the country will see a doubling of its current wave of cases.
-
China approves Merck antiviral as it battles COVID-19 wave
China approves Merck antiviral as it battles COVID-19 wave
-
Mersana Inks Cancer Therapy Development Deal With Merck Germany
Mersana Therapeutics Inc (NASDAQ: MRSN) signed a deal for developing antibody-drug conjugates (ADCs) for cancer treatment with Germany's Merck KGaA (OTC: MKGAF) (OTC: MKKGY). Mersana would...
-
Merck COVID Antiviral Does Not Reduce Risk Of Hospitalization, Death Rates In Vaccinated Individuals
According to a large study, dubbed PANORAMIC, Merck & Co Inc's (NYSE: MRK) COVID-19 antiviral molnupiravir speeds up recovery but does not reduce the hospitalization or death rate in...
-
Mersana signs deal with Merck KGaA for cancer therapy development
(Reuters) – Mersana Therapeutics Inc said on Thursday it had signed a deal for developing cancer drugs with Germany’s Merck KGaA that has the potential to generate up to $800 million in...
-
Merck, Kelun-Biotech Ink Licensing Pact For Seven Cancer Candidates
Merck & Co Inc (NYSE: MRK) and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co Ltd) have entered into an exclusive license and collaboration agreement to develop seven...
-
Merck, Sichuan Kelun enter cancer collaboration, with milestone payments up to $9.3 billion
Merck & Co. Inc. said Thursday that it entered into an agreement with Sichuan Kelun Pharmaceutical Co. Ltd. to develop seven new cancer therapies. Merck will pay the Chinse biotech an...
-
After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm
Merck & Co Inc (NYSE: MRK) has notified NGM Biopharmaceuticals Inc (NASDAQ: NGM) that it will not exercise its option to license NGM621 and its related compounds. Merck will also not...
-
Moderna stock target raised at Morgan Stanley as analysts see $30B+ market for PCV
By Senad Karaahmetovic Morgan Stanley analysts raised the price target on Moderna (NASDAQ:MRNA) stock to $209 per share from the prior $170 after updating the model to account for the...
-
West Africa-Based Studies Show JNJ, Merck's Ebola Vaccines Provide Lasting Antibodies
Ebola vaccines developed by Johnson & Johnson (NYSE: JNJ) and Merck & Co Inc (NYSE: MRK) produced virus-fighting antibodies and appeared to be safe in children and adults, two studies...
-
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
The FDA will extend the Prescription Drug User Fee Act (PDUFA) date for AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) supplemental marketing application for Lynparza...
-
Today's most important downgrades
By Davit Kirakosyan Best Buy Co Inc (NYSE:BBY) shares fell more than 3% today after BofA Securities downgraded the company to Underperform from Neutral and lowered its price target to...
-
Midday movers: Delta Air Lines, Aspen Group, Charter Communications and more
By Liz Moyer Investing.com -- Stocks were rising on Wednesday as investors prepared to hear the Federal Reserve's decision on interest rates and forecasts for the economy. Here are the...
-
Moderna stock downgraded after 'enthusiastic reception' of cancer vaccine data
By Senad Karaahmetovic Moderna (NASDAQ:MRNA) shares surged nearly 20% yesterday after the company’s mRNA cancer vaccine, developed together with Merck & Company Inc (NYSE:MRK), met the...
-
Microdermabrasion Devices Market Report (2022 to 2030) - Novartis AG, Pfizer Inc., Sanofi AG, Merck & Co. Inc. and GSK Plc
Pune, Dec. 14, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global microdermabrasion devices market is expected to clock US$ 1,042.4...
-
Wall St rises after CPI data but Fed concerns persist; Moderna, Merck shares up
The benchmark S&P 500 jumped as much as 2.76% to a three-month high early in the trading session on news that November.
-
Midday movers: Moderna, United Airlines, Pinterest and more
By Liz Moyer Investing.com -- Stocks gave back most of their early gains on Tuesday after the November inflation report showed prices cooling more than expected. Here are the midday movers...
-
Moderna shares surge on cancer vaccine data
By Sam Boughedda Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) shares rose Tuesday morning after the companies said mRNA-4157/V940, an investigational mRNA cancer vaccine, in combination...
-
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%
By Julie Steenhuysen and Michael Erman CHICAGO (Reuters) -A combination of Moderna Inc’s experimental melanoma vaccine and Merck & Co’s blockbuster immunotherapy Keytruda cut the risk of...
-
Moderna-Merck Partnered Cancer Vaccine Meets Primary Efficacy Endpoint, Stock Jumps
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940 combined with Keytruda met its primary endpoint. Results...
-
Merck, Moderna say mRNA vaccine and Keytruda lowers the risk of death in melanoma patients
Merck & Co. Inc. and Moderna Inc. said Tuesday that their experimental mRNA-based cancer vaccine reduced the risk of recurrence or death when used with Merck's Keytruda in patients with...
-
Indonesia to produce Merck’s HPV vaccines to combat cervical cancer
JAKARTA (Reuters) – Indonesia will produce drugmaker Merck & Co’s vaccines for human papillomavirus (HPV), the chief of its state-owned pharmaceutical company Bio Farma said on Tuesday,...
-
Amgen secures $28.3 billion deal to buy Horizon Therapeutics
By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about $28.3 billion,...
-
Sanofi shares rise after French drugmaker ditches Horizon deal talks
By Scott Kanowsky Investing.com -- Shares in Sanofi SA (EPA:SASY) rose on Monday after the French drugmaker backed out of its plans to bid for biotech company Horizon Therapeutics PLC...
-
In case you missed it, 6 big dividend hikes: Owens Corning raises by 49%
Here are the biggest fresh dividend hikes and special dividends, as first covered on InvestingPro+, including several predicted by data from Investing.com and StreetInsider last weekend. Get...
-
Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot
By Michael Erman (Reuters) – U.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it...
-
13 dividend hikes to watch for this week: McCormick, Merck
Companies often establish a pattern of hiking dividends at the same time each year, giving investors a reliable cash influx and enticing them to stick around for the long term. With help...
-
6 biggest deal reports this week: Manchester United open to selling the club
Here are 6 head-turning deal dispatches from the past week, as covered first on InvestingPro+. 1. Activision Blizzard (NASDAQ:ATVI) stock slipped this week after Politico reported the U.S....
-
Mirati Therapeutics seen worth more than double in a buyout
By Investing.com Staff After surging nearly 16% Tuesday on fresh takeover rumors, Mirati Therapeutics (NASDAQ:MRTX) is adding another 5% Wednesday as Wall Street analysts weigh in on the...
-
Disney, Imago BioSciences rise premarket; Coinbase, Carvana fall
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, November 21st. Please refresh for updates. Walt Disney (NYSE:DIS) stock soared 8.5% after the...
-
Credit Suisse initiates coverage of large-cap pharma stocks - Merck started at outperform
By Sam Boughedda Credit Suisse analysts said Friday that the firm is initiating coverage of U.S. large-cap pharmaceuticals with four Outperform ratings, two Neutral ratings, and one...
-
2 rumors lighting up trading screens today
By Investing.com Staff Stocks staged an explosive rally on Thursday after the CPI report was cooler than expected, which stoked hopes the Fed will slow the pace of rate increases sooner...
-
Seagen's announcement likely confirms it will remain a standalone company - Raymond James
By Sam Boughedda Raymond James analysts told investors in a note Thursday that Seagen Inc (NASDAQ:SGEN) announcing David Epstein as their new Chief Executive Officer and member of the board...
-
Merck Pops After Beat-and-Raise, Analysts Praise a 'Strong' Beat
By Senad Karaahmetovic Merck & Company Inc (NYSE:MRK) delivered higher-than-expected top and bottom-line numbers for its third quarter, allowing it to raise its full-year guidance. Merck...
-
Merck Tops Q3 EPS by 10c
Merck (MRK) reported Q3 EPS of $1.85, $0.10 better than the analyst estimate of $1.75. Revenue for the quarter came in at $15 billion versus the consensus estimate of $14.07...
-
Stock Market Today: Dow Ends Flat as Fed Fears Overshadow Pop in Pepsi
By Yasin Ebrahim Investing.com -- The Dow slipped Wednesday, as the Federal Reserve’s September minutes signaling higher for longer rates overshadowed a surge in Pepsi following...
-
Moderna Shares Surge 14% After Merck Option Exercise
By Senad Karaahmetovic Shares of Moderna (NASDAQ:MRNA) are up about 14% in pre-market Wednesday trading after Merck (NYSE:MRK) exercised its option to jointly develop and commercialize a...
-
Today's Most Important Upgrades
By Davit Kirakosyan Guggenheim upgraded Merck & Company Inc (NYSE:MRK) to Buy from Neutral with a price target of $104.00. According to the analysts, the company is poised to beat 2023...
-
Merck Shares Rally, Analysts Believe Data Supports Approval of Sotatercept in PAH
By Sam Boughedda Merck (NYSE:MRK) announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept on Monday. The company said...
-
Rivian, Ford Shares Slide Premarket; Toast, Fortinet Rise
By Scott Kanowsky Investing.com -- Stocks in focus in premarket trade on Monday, October 10th. Please refresh for updates. Rivian Automotive Inc (NASDAQ:RIVN) shares slumped after the...
-
Stock Market Today: Dow Ends Lower as Post-Fed Stumble Continues
By Yasin Ebrahim Investing.com -- The Dow cut some losses Thursday, but remained firmly in the red as growth sectors of the market including consumer and tech stocks floundered on fears that...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
